China National Accord Medicines Corporation Ltd.
The Third Quarterly Report for 2019
October 2019
Section I. Important Notice
Board of Directors, Supervisory Committee, all directors, supervisors and senior executives of China National Accord Medicines Corporation Ltd. (hereinafter referred to as the Company) hereby confirm that there are no any fictitious statements, misleading statements, or important omissions carried in this report, and shall take all responsibilities, individual and/or joint, for the reality, accuracy and completion of the whole contents.
All directors are present the meeting of the Board for deliberating the Third Quarter Report of the Company in person.
Lin Zhaoxiong, person in charge of the Company, head of the accounting works Wei Pingxiao and WangYing, accounting body principals (accountant in charge) hereby confirm that the Financial Report of the Third Quarterly Report is authentic, accurate and complete.
Section II. Basic information of Company
I. Main accounting data andfinancialindexes
Whether ithasretroactive adjustmentor re-statementon previousaccounting data ornot□Yes√No
||||||||
|-|-|-|-|-|-|-|
||Currentperiod-end||Period-endoflastyear||Increase/decrease||
|Totalassets(RMB)|34,816,993,187.67||28,930,300,519.97||20.35%||
|Netassetsattributabletoshareholdersoflistedcompany(RMB)|12,451,750,624.00||11,618,432,603.28||7.17%||
||Currentperiod|Increase/decreaseincomparisonwithsameperiodoflastyear||Year-begintoendofthePeriod||Increase/decreaseincomparisonwithyear-begintoperiod-endoflastyear|
|Operatingrevenue(RMB)|13,647,793,431.64|24.21%||38,875,940,809.07||22.38%|
|Netprofitattributabletoshareholdersofthelistedcompany(RMB)|311,310,706.52|9.14%||962,144,066.92||3.79%|
|Netprofitattributabletoshareholdersofthelistedcompanyafterdeductingnon-recurringgainsandlosses(RMB)|303,365,280.52|7.45%||943,065,728.47||4.14%|
|Netcashflowarisingfromoperatingactivities(RMB)|--|--||1,072,962,161.22||90.24%|
|Basicearningspershare(RMB/Share)|0.735|10.36%||2.247||3.79%|
|Dilutedearningspershare(RMB/Share)|0.735|10.36%||2.247||3.79%|
|WeightedaverageROE|2.53%|0.09percentagepointsdecline||7.94%||1.27percentagepointsdecline|

 Note:theweightedaverageROEhas0.09percentagepointsdownfromsameperiodlastyear,and1.27percentagepointsdownat year-begintoperiod-endoversameperiodlastyear,mainlybecauseastrategyinvestorwasintroducedbyGuodaDrugstorein secondhalfoflastyear.
Itemsandamountofextraordinaryprofit(gains)/losses
√Applicable □Notapplicable
InRMB
||||
|-|-|-|
|Item|Amountfromyear-begintoendofthePeriod|Note|
|Gains/lossesfromthedisposalofnon-currentasset(includingthewrite-offthataccruedforimpairmentofassets)|487,779.48||
|Governmentalsubsidyreckonedintocurrentgains/losses(notincludingthesubsidyenjoyedinquotaorrationaccordingtonationalstandards,whicharecloselyrelevanttoenterprise’sbusiness)|29,325,892.83|Receivedvarytaxessubsidiesandfinancialrewardsintheperiod|
|Reversalofimpairmentreserveforaccountreceivablewithseparateimpairmenttesting|1,216,744.26|Netgain/lossofimpairmentprovisionswitch-backforreceivables|
|Gains/lossesonentrustedloans|2,563,975.31|ThegainsobtainedfromofferingentrustloanstoChinaNationalZhijun(Suzhou)|
|Othernon-operatingincomeandexpenditureexceptfortheaforementioneditems|2,455,770.91||
|Othergains/lossessatisfyadefinitionofextraordinarygains/losses|22,424.73||
|Less:impactonincometax|8,393,659.91||
|Impactonminorityshareholders’equity(post-tax)|8,600,589.16||
|Total|19,078,338.45|--|

Concerning the extraordinary profit (gain)/loss defined byQ&A Announcement No.1 on Information Disclosure for Companies OfferingTheirSecuritiestothePublic---ExtraordinaryProfit/loss,andtheitemsdefinedasrecurringprofit(gain)/lossaccordingto the lists of extraordinary profit (gain)/loss inQ&A Announcement No.1 on Information Disclosure for Companies Offering Their SecuritiestothePublic---ExtraordinaryProfit/loss,explainreasons
□Applicable√Notapplicable
In reporting period, the Company has no particular about items defined as recurring profit (gain)/loss according to the lists of extraordinary profit (gain)/loss inQ&AAnnouncement No.1on Information Disclosurefor Companies Offering TheirSecuritiesto thePublic---ExtraordinaryProfit/loss.
II. Statement of the total shareholders and shares-held of top ten shareholders at end of the Period
1.Totalnumberofcommonshareholdersattheendofthisreportperiodandtoptencommonshareholders InShare
|||||
|-|-|-|-|
|Total common shareholders at theendofreportperiod|21,620|Total preference shareholderswithvotingrightsrecoveredatend of reporting period (ifapplicable)|0|

||||||||
|-|-|-|-|-|-|-|
|Toptenshareholders|||||||
|Shareholders|Natureofshareholder|Proportionofsharesheld|Amountofsharesheld|Amountofrestrictedsharesheld|Numberofsharepledged/frozen||
||||||Stateofshare|Amount|
|SinopharmGroupCo.,Ltd.|State-ownedcorporate|56.06%|239,999,991|55,057,700|||
|HongKongSecuritiesClearingCompanyLtd|Overseascorporate|4.48%|19,163,870||||
|HTHK/CMGFSGUFP-CMGFIRSTSTATECHINAGROWTHFD|Overseascorporate|2.68%|11,469,644||||
|ChinaNationalPharmaceuticalForeignTradeCorp.|State-ownedcorporate|1.24%|5,323,043|5,323,043|||
|FidelityInvestmentManagement(HongKong)Limited-Client’sfund|Overseascorporate|1.13%|4,825,907||||
|#BeijingHaoqingFortuneInvestmentManagementCo.,Ltd.–HaoqingValueStableNo.8InvestmentFund|Domesticnonstate-ownedcorporate|0.96%|4,118,716||||
|Basicendowmentinsurancefund-portfolio1003|Domesticnonstate-ownedcorporate|0.95%|4,080,913||||
|CentralHuijinInvestmentLtd.|State-ownedcorporate|0.89%|3,804,400||||
|BankofChina-HarvestHealthCareStockSecurities|Domesticnonstate-ownedcorporate|0.76%|3,258,525||||

|||||||
|-|-|-|-|-|-|
|InvestmentFunds||||||
|BBHBOSS/AFIDELITYFD-CHINAFOCUSFD|Overseascorporate|0.76%|3,246,061|||
|Particularabouttoptenshareholderswithun-restrictsharesheld||||||
|Shareholders||Amountofun-restrictsharesheld||Typeofshares||
|||||Type|Amount|
|SinopharmGroupCo.,Ltd.||184,942,291||RMBordinaryshares|184,942,291|
|HongKongSecuritiesClearingCompanyLtd||19,163,870||RMBordinaryshares|19,163,870|
|HTHK/CMGFSGUFP-CMGFIRSTSTATECHINAGROWTHFD||11,469,644||Domesticallylistedforeignshares|11,469,644|
|ChinaNationalPharmaceuticalForeignTradeCorp.||5,323,043||RMBordinaryshares|5,323,043|
|FidelityInvestmentManagement(HongKong)Limited-Client’sfund||4,825,907||RMBordinaryshares|4,825,907|
|#BeijingHaoqingFortuneInvestmentManagementCo.,Ltd.–HaoqingValueStableNo.8InvestmentFund||4,118,716||RMBordinaryshares|4,118,716|
|Basicendowmentinsurancefund-portfolio1003||4,080,913||RMBordinaryshares|4,080,913|
|CentralHuijinInvestmentLtd.||3,804,400||RMBordinaryshares|3,804,400|
|BankofChina-HarvestHealthCareStockSecuritiesInvestmentFunds||3,258,525||RMBordinaryshares|3,258,525|
|BBHBOSS/AFIDELITYFD-CHINAFOCUSFD||3,246,061||Domesticallylistedforeignshares|3,246,061|
|Explanationonassociatedrelationshipamongtheaforesaidshareholders||ItisunknownthatthereexistsnoassociatedrelationshiporbelongstotheconsistentactionistamongtheothertradableshareholdersregulatedbytheManagementMeasureofInformationDisclosureonChangeofShareholdingforListedCompanies.||||
|Explanationontoptencommonshareholdersinvolvingmarginbusiness(ifapplicable)||BeijingHaoQingWealthInvestmentManagementCo.,Ltd.–HaoQingValueStableNo.8InvestmentFundholds4,048,216sharesoftheCompanythroughmargintradingandrefinancingsecuredsecurityaccount||||

Whether top ten common shareholders or top ten common shareholders with un-restrict shares held have a buy-back agreement
dealinginreportingperiod
□Yes√No
TheshareholdersoftheCompanyhavenobuy-backagreementdealinginreportingperiod.
2.Totalofshareholderswithpreferredstockheldandthetoptenshareholdings
□Applicable √Notapplicable
Section III. Important events
I. Particular about major changes from items of main accounting statements and financial indexes as wellas reasons
√Applicable□Notapplicable
1.Notereceivable:decreased772millionYuanoverthatofperiod-beginwithgrowthrateof-56.88%,mainlybecauseaccordingto thepresentationrequirementsofstatement,atendoftheperiod,thebankacceptancebillinnotereceivablewaslistedundertheitem of“Receivablefinancing”;
2.Accountsreceivable:increased3844millionYuanoverthatofperiod-beginwithgrowthrateof41.17%,mainlybecausevolume ofbusinessincreasedintheperiod,accountreceivablegoesupandpaymentcollectionperiodincreasedatthesametime;
3.Receivablefinancing:increased400millionYuanoverthatofperiod-begin,mainlybecauseaccordingtothepresentation requirementsofstatement,atendoftheperiod,thebankacceptancebillinnotereceivablewaslistedundertheitemof“Receivable financing”;
4. Interest receivable: increased 6.1777 million Yuan over that of period-begin with growth rate of75.12%, mainly because the depositinterestincreased;
5. Right-of-use assets: increased 1860 million Yuan over that of period-begin, mainly due to the implementation of new leasing standardsintheperiod;
6.Totalnon-currentassets:increased2114millionYuanoverthatofperiod-beginwithgrowthrateof47.66%,mainlybecausethe right-of-useassetsincreasedfornewleasingstandardsimplementedintheperiod;
7.Accountspayable:increased2678millionYuanoverthatofperiod-beginwithgrowthrateof41.41%,mainlybecausevolumeof businessincreasedintheperiod,purchasevolumeandaccountpayableincreaseaccordingly;
8. Dividends payable: increased 4.7064 million Yuan over that of period-begin with growth rate of73.66%, mainly because the accrualofbonusofminorityshareholderspayableincreased;
9.Non-currentliabilitiesduewithinoneyear:increased533millionYuanoverthatofperiod-beginwithgrowthrateof9,093.11%, mainlyduetotheimplementationofnewleasingstandardsintheperiod,theendingbookvalueofleasingliabilitiesduefor repaymentwithinoneyearfromthebalancesheetdate,waslistedundertheitemof“Non-currentliabilitiesduewithinoneyear”;10.Othercurrentliabilities:increased330,700Yuanoverthatofperiod-beginwithgrowthrateof113.07%,mainlybecausethe outputtaxamountreadyfortransferincreasedoverthatofperiod-begin;
11.Long-termborrowings:decreased31.60millionYuanoverthatofperiod-beginwithgrowthrateof-100.00%,mainlybecause thelong-termloanwasre-classifiedtonon-currentliabilityduewithinoneyear;
12.Leaseliabilities:increased1165millionYuanoverthatofperiod-begin,mainlyduetotheimplementationofnewleasing standardsintheperiod;
13.Long-termpayables:decreased3.764millionYuanoverthatofperiod-beginwithgrowthrateof-82.47%,mainlyduetothe implementationofnewleasingstandardsintheperiod,thefinanceleasebeforethefirstexecutiondatewasadjustedtolease liabilities;
14.Totalnon-currentliabilities:increased1126millionYuanoverthatofperiod-beginwithgrowthrateof422.45%,mainlybecause leaseliabilitiesincreasedfortheimplementationofnewleasingstandardsintheperiod;
15.Totalliabilities:increased4875millionYuanoverthatofperiod-beginwithgrowthrateof32.44%,mainlybecausevolumeof businessincreasedintheperiod,purchasevolumeandaccountpayableincreaseaccordingly;
16.Operatingrevenue:increased7109millionYuanonay-o-ybasiswithgrowthrateof22.38%,mainlybecausebusinessincome increasedforthegoodbusinessperformanceintheperiod;
17. Operating costs: increased 6552 million Yuan on a y-o-y basis with growth rate of23.30%, mainly because business income increasedforthegoodbusinessperformanceintheperiod,businesscostincreasedcorrespondingly;
18.Financecosts:increased69.5683millionYuanonay-o-ybasiswithgrowthrateof88.87%,mainlyduetotheimplementationof new leasing standards in the period, during the lease terms, interest expenses shall be calculated according to the discount rate for leaseliabilities,therewasnosuchiteminthesameperiodlastyear;
19. Other incomes: increased 14.7031 million Yuan on a y-o-y basis with growth rate of118.53%, mainly because fiscal subsidy receivedinperiodincreased;
20. Impairment losses on financial assets: increased 15.1252 million Yuan on a y-o-y basis with growth rate of3156.28%, mainly becausetheaccountreceivablehasincreasedoversameperiodlastyearatendoftheperiod,thanthebaddebtprovisionaccrualin theperiodincreasedonay-o-ybasis;
21.Impairmentlosses:increased714,900Yuanonay-o-ybasiswithgrowthrateof613.43%,mainlybecausereversalofthe inventoryfallingpricereservesdeclinedfromayearearlier;
22.Gainondisposalofassets:decreased3.7735millionYuanonay-o-ybasiswithgrowthrateof-86.59%,mainlybecauseatsame periodlastyear,therewasapropertyfundscollectedbythegovernmentwasreceivedbytheCompanywhilenosuchiteminthe period;
23.Minorityshareholders’gainsandlosses:increased81.7569millionYuanonay-o-ybasiswithgrowthrateof97.93%,mainly becauseatsecondhalfof2018,subsidiaryGuodaDrugstoreintroducedastrategyinvestor,thegains/lossesofminorityshareholders increasedonay-o-ybasisintheperiod;
24.Totalcomprehensiveincomeattributabletominorityshareholders:increased81.7569millionYuanonay-o-ybasiswithgrowthrateof97.93%,mainlybecauseatsecondhalfof2018,subsidiaryGuodaDrugstoreintroducedastrategyinvestor,thetotal comprehensiveincomeattributabletominorityshareholdersincreasedcorrespondingly;
25.Taxrefunds:increased1.7933millionYuanonay-o-ybasiswithgrowthrateof104.58%,mainlybecausethetaxrefund increasedcomparedwithsameperiodoflastyear;
26.Cashpaymentsrelatedtootheroperatingactivities:decreased484millionYuanonay-o-ybasiswithgrowthrateof-38.77%, mainlyduetotheimplementationofnewleasingstandardsintheperiod,therentspaidintheperiodarereckonedintocashpaidwith otherfinancingactivityconcerned,whilenosuchitematsameperiodlatyear;
27.Netcashflowsfromoperatingactivities:increased509millionYuanonay-o-ybasiswithgrowthrateof90.24%,mainlydueto thegoodoperationperformance,cashreceivedforgoodssalesandprovidingservicesincreasedcorrespondingly;andduetothe implementationofnewleasingstandardsintheperiod,therentspaidintheperiodarereckonedintocashpaidwithotherfinancing activityconcerned,whilenosuchitematsameperiodlatyear;
28.Cashreceivedfromreturnsoninvestments:decreased52.7204millionYuanonay-o-ybasiswithgrowthrateof-40.26%, mainlybecausetheinvestmentdividendreceivedfromjointventuredeclinedonay-o-ybasis;
29.Cashreceivedwithotherinvestingactivities:decreased96.7471millionYuanonay-o-ybasiswithgrowthrateof-95.54%, mainlybecauseatsameperiodlastyear,receivedaconsiderationforreorganizationofShyndecPharmaceutical,whilenosuchitem intheperiod;
30.Subtotalofcashin-flowfrominvestingactivities:decreased150millionYuanonay-o-ybasiswithgrowthrateof-63.14%, mainlybecausetheinvestmentdividendreceivedfromjointventuredeclinedonay-o-ybasis;andatsameperiodlastyear,received aconsiderationforreorganizationofShyndecPharmaceutical,whilenosuchitemintheperiod;
31.Netcashpaidfromdisposalofsubsidiariesandotherbusinessunits:increased5.328millionYuanonay-o-ybasis,mainlydueto theinvestmentamountfornewcompanyacquisitionintheperiod,whilenosuchitematsameperiodlastyear;
32.Cashpaymentsrelatedtootherinvestingactivities:decreased78.3182millionYuanonay-o-ybasiswithgrowthrateof-97.99%, mainlybecauseatsameperiodlastyear,theentrustedloansofSinopharmZhijun(Suzhou)waspaidwhilenosuchiteminthe period;
33.Netcashflowsfrominvestingactivities:decreased84.2184millionYuanonay-o-ybasiswithgrowthrateof-102.33%,mainly becausetheinvestmentdividendreceivedfromjointventuredeclinedonay-o-ybasis;andatsameperiodlastyear,receiveda considerationforreorganizationofShyndecPharmaceutical,whilenosuchitemintheperiod;
34.Cashproceedsfrominvestmentsbyothers:decreased2744millionYuanonay-o-ybasiswithgrowthrateof-98.40%,mainly becauseatsameperiodlastyear,subsidiaryGuodaDrugstorereceivedacapitalincreasedamountfromstrategyinvestor,whileno suchitemintheperiod;
35.Cashreceivedfromborrowings:decreased32.9702millionYuanonay-o-ybasiswithgrowthrateof-66.38%,mainlybecause thebankcurrentloansintheperioddeclinedonay-o-ybasis;
36.Cashreceiptsrelatedtootherfinancingactivities:decreased107millionYuanonay-o-ybasiswithgrowthrateof-98.19%, mainlybecauseatsameperiodlastyear,receivedamoneyordersecuritywhilenosuchitemintheperiod;
37.Sub-totalofcashinflowsfromfinancingactivities:decreased2884millionYuanonay-o-ybasiswithgrowthrateof-97.86%, mainlybecauseatsameperiodlastyear,subsidiaryGuodaDrugstorereceivedacapitalincreasedamountfromstrategyinvestor, whilenosuchitemintheperiod;
38.Cashpaymentsfordistributionofdividendsorprofitandinterestexpenses:increased174millionYuanonay-o-ybasiswithgrowthrateof62.86%,mainlybecausetheinterestofsupplychainfinancingincreasedonay-o-ybasisintheperiod;
39.Cashpaymentsrelatedtootherfinancingactivities:increased544millionYuanonay-o-ybasiswithgrowthrateof896.87%, mainlyduetotheimplementationofnewleasingstandardsintheperiod,therentspaidintheperiodarereckonedintocashpaidwith otherfinancingactivityconcerned,whilenosuchitematsameperiodlatyear;
40.Sub-totalofcashoutflowsfromfinancingactivities:increased712millionYuanonay-o-ybasiswithgrowthrateof170.65%, mainlyduetotheimplementationofnewleasingstandardsintheperiod,therentspaidintheperiodarereckonedintocashpaidwith otherfinancingactivityconcernedandtheinterestofsupplychainfinancingincreasedonay-o-ybasisintheperiod;
41.Netcashflowsfromfinancingactivities:decreased3596millionYuanonay-o-ybasiswithgrowthrateof-142.10%,mainly becauseatsameperiodlastyear,subsidiaryGuodaDrugstorereceivedacapitalincreasedamountfromstrategyinvestor,whileno suchitemintheperiod;
42.Eefectofforeignexchangeratechangesoncashandcashequivalents:increased138,500Yuanonay-o-ybasiswithgrowthrateof44.04%,mainlyduetotheimpactofexchangeratechanges;
43.Netincreaseincashandcashequivalents:decreased3171millionYuanonay-o-ybasiswithgrowthrateof-105.28%,mainly becauseatsameperiodlastyear,subsidiaryGuodaDrugstorereceivedacapitalincreasedamountfromstrategyinvestor,whileno suchitemintheperiod;
44.Cashandcashequivalentsatbeginningoftheyear:increased3959millionYuanonay-o-ybasiswithgrowthrateof107.76%, mainlybecauseatsecondhalfoflastyear,subsidiaryGuodaDrugstorereceivedacapitalincreasedamountfromstrategyinvestor, whilenosuchitematperiod-beginoflastyear.
II. Progress andinfluenceofthe mainevents as wellas solutionanalysisspecification
□Applicable√Notapplicable
Progressofsharesbuy-back
□Applicable√Notapplicable
Implementationprogressofthereductionofrepurchasessharesbycentralizedbidding
□Applicable√Notapplicable
III. Commitments that the company, shareholders, actual controller, offeror, directors, supervisors, senior management or other related parties have fulfilled during the reporting period andhavenotyet fulfilledby theend ofreporting period
□Applicable√Notapplicable
There are no commitments that the company, shareholders, actual controller, offeror, directors, supervisors, senior management or otherrelatedpartieshavefulfilledduringthereportingperiodandhavenotyetfulfilledbytheendofreportingperiod.
IV.Particular aboutsecurity investment
□Applicable√Notapplicable
TheCompanyhadnosecurityinvestmentinPeriod.
V. Trustfinancing
□Applicable√Notapplicable
TheCompanyhadnotrustfinancinginPeriod.
VI.Particulars aboutderivatives investment
□Applicable√Notapplicable
TheCompanyhadnoderivativesinvestmentinPeriod.
VII. Registration form of receiving research, communication and interview in the report period
□Applicable√Notapplicable
TheCompanyhasnoresearch,communicationandinterviewacceptedinthePeriod.
VIII. Guarantee outsideagainsttheregulation
□Applicable√Notapplicable
TheCompanyhadnoguaranteeoutsideagainsttheregulationinthereportingperiod.
IX.Non-operational fund occupationfromcontrolling shareholders andits related party□Applicable√Notapplicable
TheCompanyhadnonon-operationalfundoccupationfromcontrollingshareholdersanditsrelatedparty.
Section IV. Financial Statement
I. Financialstatement
1.Consolidatebalancesheet
PreparedbyChinaNationalAccordMedicinesCorporationLtd.
2019-09-30
InRMB
||||
|-|-|-|
|Item|2019-9-30|2018-12-31|
|Currentassets:|||
|Monetaryfunds|7,810,810,868.51|8,089,781,304.56|
|Settlementprovisions|||
|Capitallent|||
|Tradablefinancialassets|||
|Financialassetsmeasuredbyfairvalueandwithvariationreckonedintocurrentgains/losses|||
|Derivativefinancialassets|||
|Notereceivable|585,211,751.81|1,357,311,929.63|
|Accountreceivable|13,181,036,029.36|9,336,861,647.92|
|Receivablefinancing|400,387,183.26||
|Advancestosuppliers|424,448,767.10|583,484,515.95|
|Insurancereceivable|||
|Reinsurancereceivables|||
|Contractreserveofreinsurancereceivable|||
|Otherreceivables|522,497,740.14|643,493,359.32|
|Including:Interestreceivable|14,401,063.47|8,223,327.64|
|Dividendreceivable|||
|Buyingbackthesaleoffinancialassets|||
|Inventories|5,274,930,261.55|4,389,335,942.19|
|Contractualassets|||
|Assetsheldforsale|||

||||
|-|-|-|
|Non-currentassetduewithinoneyear|||
|Othercurrentassets|69,262,261.99|95,347,629.18|
|Totalcurrentassets|28,268,584,863.72|24,495,616,328.75|
|Non-currentassets:|||
|Loansandpaymentsonbehalf|||
|Debtinvestment|||
|Financeassetavailableforsales|||
|Otherdebtinvestment|||
|Held-to-maturityinvestment|||
|Long-termaccountreceivable|||
|Long-termequityinvestment|2,107,690,039.44|1,880,393,786.10|
|Otherequityinstrumentsinvestment|13,685,760.00|13,685,760.00|
|Othernon-currentfinancialassets|140,000,000.00|140,000,000.00|
|Investmentproperties|139,672,194.89|144,894,495.97|
|Fixedassets|583,995,191.53|607,933,827.67|
|Constructioninprogress|35,681,041.39|36,412,614.61|
|Productivebiologicalasset|||
|Oilandgasasset|||
|Right-of-useassets|1,860,064,348.67||
|Intangibleassets|314,251,903.10|319,207,126.15|
|ExpenseonResearchandDevelopment|||
|Goodwill|871,041,800.60|833,547,800.60|
|Long-termprepaidexpenses|330,156,094.79|311,328,706.46|
|Deferredtaxassets|78,340,768.87|74,914,209.95|
|Othernon-currentasset|73,829,180.67|72,365,863.71|
|Totalnon-currentasset|6,548,408,323.95|4,434,684,191.22|
|Totalassets|34,816,993,187.67|28,930,300,519.97|
|Currentliabilities:|||
|Short-termborrowings|2,417,214,478.23|2,597,652,702.43|
|Loanfromcentralbank|||
|Capitalborrowed|||
|Transactionalfinancialliability|||

||||
|-|-|-|
|Financialliabilitymeasuredbyfairvalueandwithvariationreckonedintocurrentgains/losses|||
|Derivativefinancialliability|||
|Notepayable|4,087,524,569.31|3,416,755,681.80|
|Accountpayable|9,146,870,315.29|6,468,535,961.17|
|Accountsreceivedinadvance|||
|Contractualliability|226,493,600.53|255,590,612.37|
|Sellingfinancialassetofrepurchase|||
|Absorbingdepositandinterbankdeposit|||
|Securitytradingofagency|||
|Securitysalesofagency|||
|Employeebenefitspayable|208,422,163.84|231,866,407.40|
|Taxespayable|240,761,116.26|241,980,412.72|
|Otheraccountpayable|1,639,777,109.48|1,539,436,971.93|
|Incl:Interestpayable|23,295,353.88|21,906,660.63|
|Dividendpayable|11,095,744.80|6,389,320.96|
|Commissionchargeandcommissionpayable|||
|Reinsurancepayable|||
|Liabilityheldforsale|||
|Non-currentliabilitiesduewithinoneyear|538,837,869.81|5,861,324.37|
|Othercurrentliabilities|623,159.83|292,465.75|
|Totalcurrentliabilities|18,506,524,382.58|14,757,972,539.94|
|Non-currentliabilities:|||
|Insurancecontractreserve|||
|Long-termborrowings||31,600,000.00|
|Bondspayable|||
|Including:Preferredstock|||
|Perpetualcapitalsecurities|||
|Leaseliability|1,165,308,548.15||
|Long-termpayable|800,000.00|4,563,978.52|

||||
|-|-|-|
|Long-termemployeebenefitspayable|1,915,000.00|2,050,000.00|
|Accrualliability|||
|Deferredincome|90,111,450.25|91,491,170.40|
|Deferredtaxliabilities|66,067,559.30|67,605,161.88|
|Othernon-currentliabilities|68,388,290.57|69,241,176.18|
|Totalnon-currentliabilities|1,392,590,848.27|266,551,486.98|
|Totalliabilities|19,899,115,230.85|15,024,524,026.92|
|Owner’sequity:|||
|Sharecapital|428,126,983.00|428,126,983.00|
|Otherequityinstrument|||
|Including:Preferredstock|||
|Perpetualcapitalsecurities|||
|Capitalsurplus|4,363,409,728.51|4,320,984,981.51|
|Less:Inventoryshares|||
|Othercomprehensiveincome|||
|Reasonablereserve|||
|Surplusreserve|214,063,491.50|214,063,491.50|
|Provisionofgeneralrisk|||
|Retainedearnings|7,446,150,420.99|6,655,257,147.27|
|Shareholders’equityattributabletoshareholdersoftheparent|12,451,750,624.00|11,618,432,603.28|
|Non-controllinginterests|2,466,127,332.82|2,287,343,889.77|
|Totalshareholders’equity|14,917,877,956.82|13,905,776,493.05|
|Totalliabilitiesandshareholders’equity|34,816,993,187.67|28,930,300,519.97|

 Legalrepresentative:LinZhaoxiong
Personinchargeofaccountingworks:WeiPingxiao
Personinchargeofaccountinginstitution:WangYing
2.BalanceSheetofParentCompany
InRMB
||||
|-|-|-|
|Item|2019-9-30|2018-12-31|
|Currentassets:|||
|Cashandbankbalances|2,544,212,671.60|1,817,654,598.01|
|Tradablefinancialassets|||

||||
|-|-|-|
|Financialassetsmeasuredbyfairvalueandwithvariationreckonedintocurrentgains/losses|||
|Derivativefinancialassets|||
|Notereceivable|33,503,980.32|63,870,980.39|
|Accountreceivable|759,614,729.17|631,236,593.94|
|Receivablefinancing|16,673,997.31||
|Advancestosuppliers|3,026,025.81|4,760,182.00|
|Otherreceivable|1,866,735,563.06|1,541,980,883.50|
|Including:Interestreceivable|16,497,156.40|7,550,877.07|
|Dividendreceivable|||
|Inventories|211,858,298.59|158,166,185.65|
|Contractualassets|||
|Assetsheldforsale|||
|Non-currentassetsmaturingwithinoneyear|||
|Othercurrentassets|39,482.38|39,482.38|
|Totalcurrentassets|5,435,664,748.24|4,217,708,905.87|
|Non-currentassets:|||
|Debtinvestment|||
|Available-for-salefinancialassets|||
|Otherdebtinvestment|||
|Held-to-maturityinvestments|||
|Long-termreceivables|||
|Long-termequityinvestments|7,693,092,094.23|7,432,906,692.24|
|Investmentinotherequityinstrument|||
|Othernon-currentfinancialassets|140,000,000.00|140,000,000.00|
|Investmentproperties|1,560,072.33|1,955,854.46|
|Fixedassets|15,474,034.96|21,362,422.03|
|Constructioninprogress|||
|Productivebiologicalassets|||
|Oilandnaturalgasassets|||
|Right-of-useassets|6,500,265.79||
|Intangibleassets|2,783,945.44|2,452,222.51|

||||
|-|-|-|
|Researchanddevelopmentcosts|||
|Goodwill|||
|Long-termdeferredexpenses|6,527,719.68|7,481,809.53|
|Deferredincometaxassets|||
|Othernon-currentassets|7,000,000.00|7,000,000.00|
|Totalnon-currentassets|7,872,938,132.43|7,613,159,000.77|
|Totalassets|13,308,602,880.67|11,830,867,906.64|
|Currentliabilities:|||
|Short-termborrowings|280,000,000.00|539,000,000.00|
|Transactionalfinancialliability|||
|Financialliabilitymeasuredbyfairvalueandwithvariationreckonedintocurrentgains/losses|||
|Derivativefinancialliability|||
|Notespayable|390,519,916.75|252,317,800.78|
|Accountpayable|630,198,511.72|442,049,241.22|
|Accountsreceivedinadvance|||
|Contractualliability|1,694,562.86|4,182,083.40|
|Employeebenefitspayable|37,876,995.85|36,233,563.12|
|Taxespayable|9,336,735.58|13,426,601.90|
|Otherpayable|1,894,492,989.75|1,481,817,856.56|
|Incl:Interestpayable|8,063,589.67|1,354,592.35|
|Dividendspayable|||
|Liabilityheldforsale|||
|Non-currentliabilitiesduewithinoneyear|32,573,100.20||
|Othercurrentliabilities|292,740.68|226,427.99|
|Totalcurrentliabilities|3,276,985,553.39|2,769,253,574.97|
|Non-currentliabilities:|||
|Long-termborrowings||31,600,000.00|
|Bondspayable|||
|Including:preferredstock|||
|Perpetualcapitalsecurities|||
|Leaseliabilities|5,715,312.04||

||||
|-|-|-|
|Long-termpayables|800,000.00|800,000.00|
|Long-termemployeebenefitspayable|102,000.00|118,000.00|
|Accruedliabilities|||
|Deferredincome|1,388,958.78|1,687,899.50|
|Deferredtaxliabilities|1,644,875.80|2,298,426.39|
|Othernon-currentliabilities|||
|Totalnon-currentliabilities|9,651,146.62|36,504,325.89|
|Totalliabilities|3,286,636,700.01|2,805,757,900.86|
|Owners’equity:|||
|Sharecapital|428,126,983.00|428,126,983.00|
|Otherequityinstrument|||
|Including:preferredstock|||
|Perpetualcapitalsecurities|||
|Capitalsurplus|4,468,787,524.26|4,426,362,777.26|
|Less:Inventoryshares|||
|Othercomprehensiveincome|||
|Specialreserve|||
|Surplusreserve|214,063,491.50|214,063,491.50|
|Retainedearnings|4,910,988,181.90|3,956,556,754.02|
|Totalshareholders’equity|10,021,966,180.66|9,025,110,005.78|
|Totalliabilitiesandshareholders’equity|13,308,602,880.67|11,830,867,906.64|

 3.ConsolidatedProfitStatement(theperiod)
InRMB
||||
|-|-|-|
|Item|CurrentPeriod|LastPeriod|
|I.Totaloperatingrevenue|13,647,793,431.64|10,987,540,368.77|
|Including:Operatingrevenue|13,647,793,431.64|10,987,540,368.77|
|Interestrevenue|||
|Insurancegained|||
|Commissionchargeandcommissionrevenue|||
|II.Totaloperatingcosts|13,305,315,433.53|10,672,195,431.17|
|Including:Operatingcosts|12,253,508,326.76|9,749,853,630.20|

||||
|-|-|-|
|Interestexpense|||
|Commissionchargeandcommissionexpense|||
|Cashsurrendervalue|||
|Netamountofexpenseofcompensation|||
|Netamountofwithdrawalofinsurancecontractreserve|||
|Bonusexpenseofguaranteeslip|||
|Reinsuranceexpense|||
|Taxandsurcharges|36,513,174.49|30,175,966.21|
|Sellingexpense|763,231,928.31|682,736,449.56|
|Administrativeexpense|208,311,402.38|188,693,332.32|
|R&Dexpense|||
|Financecosts|43,750,601.59|20,736,052.88|
|Incl:Interestcost|86,528,994.84|45,676,535.07|
|Interestincome|42,778,570.08|26,253,068.71|
|Add:otherincome|12,116,753.12|1,815,373.95|
|Investmentincome(Lossislistedwith“-”)|86,069,936.49|78,983,284.46|
|Incl:Investmentincomefromassociates|86,019,936.49|78,933,284.46|
|Theterminationofincomerecognitionforfinancialassetsmeasuredbyamortizedcost(Lossislistedwith“-”)|||
|Exchangeincome(Lossislistedwith“-”)|||
|Netexposurehedgingincome(Lossislistedwith“-”)|||
|Incomefromchangeoffairvalue(Lossislistedwith“-”)|||
|Impairmentlossesonfinancialassets(Lossislistedwith“-”)|-3,211,918.65|-547,491.37|
|Impairmentlosses(Lossislistedwith“-”)|-705,879.81|392,308.58|
|Gainondisposalofassets(Lossislistedwith“-”)|613,909.71|76,479.50|
|III.Operatingprofit(Lossislistedwith|437,360,798.97|396,064,892.72|

||||
|-|-|-|
|“-”)|||
|Add:Non-operatingincome|3,202,332.16|1,553,611.12|
|Less:Non-operatingexpense|638,789.06|374,027.37|
|IV.Totalprofit(Lossislistedwith“-”)|439,924,342.07|397,244,476.47|
|Less:Incometaxes|80,632,027.90|76,038,019.79|
|V.Netprofit(Netlossislistedwith“-”)|359,292,314.17|321,206,456.68|
|(i)Classifybybusinesscontinuity|||
|1.NetProfitfromcontinuingoperations(netlosslistedwith‘-”)|359,292,314.17|321,206,456.68|
|2.terminationofnetprofit(netlosslistedwith‘-”)|||
|(ii)Attributableto|||
|1.Ownersoftheparent|311,310,706.52|285,244,535.54|
|2.Non-controllinginterests|47,981,607.65|35,961,921.14|
|VI.Netafter-taxofothercomprehensiveincome|||
|Netafter-taxofothercomprehensiveincomeattributabletoownersofparentcompany|||
|(I)Othercomprehensiveincomeitemswhichwillnotbereclassifiedsubsequentlytoprofitofloss|||
|1.Changesofthedefinedbenefitplansthatre-measured|||
|2.Othercomprehensiveincomeunderequitymethodthatcannotbetransfertogain/loss|||
|3.Changeoffairvalueofinvestmentinotherequityinstrument|||
|4.Fairvaluechangeofenterprise'screditrisk|||
|5.Other|||
|(ii)Othercomprehensiveincomeitemswhichwillbereclassifiedsubsequentlytoprofitorloss|||
|1.Othercomprehensiveincomeunderequitymethodthatcantransfertogain/loss|||

||||
|-|-|-|
|2.Changeoffairvalueofotherdebtinvestment|||
|3.gain/lossoffairvaluechangesforavailable-for-salefinancialassets|||
|4.Amountoffinancialassetsre-classifytoothercomprehensiveincome|||
|5.Gain/lossofheld-to-maturityinvestmentsthatre-classifytoavailable-for-salefinancialasset|||
|6.Creditimpairmentprovisionforotherdebtinvestment|||
|7.Cashflowhedgingreserve|||
|8.Translationdifferencesarisingontranslationofforeigncurrencyfinancialstatements|||
|9.Other|||
|Netafter-taxofothercomprehensiveincomeattributabletominorityshareholders|||
|VII.Totalcomprehensiveincome|359,292,314.17|321,206,456.68|
|Totalcomprehensiveincomefortheyearattributabletoshareholdersoftheparent|311,310,706.52|285,244,535.54|
|Totalcomprehensiveincomefortheyearattributabletonon-controllinginterests|47,981,607.65|35,961,921.14|
|VIII.Earningspershare:|||
|(i)Basicearningspershare|0.735|0.666|
|(ii)Dilutedearningspershare|0.735|0.666|

 As for the business merger under the same control in the Period, 0Yuan net profit realized before merger by the combinedparty,thenetprofitforcombinedpartyinlastperiodwas0Yuan.
Legalrepresentative:LinZhaoxiong
Personinchargeofaccountingworks:WeiPingxiao
Personinchargeofaccountinginstitution:WangYing
4.ProfitStatementofParentCompany(theperiod)
InRMB
||||
|-|-|-|
|Item|CurrentPeriod|LastPeriod|
|I.Operatingrevenue|1,112,624,846.96|899,859,002.45|
|Less:Operatingcosts|1,064,701,021.03|856,296,603.88|
|Taxandsurcharge|1,964,184.59|1,445,734.44|
|Sellingexpenses|17,984,619.36|16,953,141.79|
|Administrativeexpenses|24,299,300.83|16,785,749.55|
|R&Dexpenses|||
|Financialcosts|-11,487,202.76|-10,270,272.65|
|Incl:Interestexpense|15,442,321.41|10,951,050.33|
|Incl:Interestincome|27,695,670.05|21,345,942.02|
|Add:otherincome|219,828.06|121,990.82|
|Investmentincome(Lossislistedwith“-”)|473,512,554.91|84,991,405.06|
|Incl:Investmentincomefromassociates|91,259,842.03|84,991,405.06|
|Theterminationofincomerecognitionforfinancialassetsmeasuredbyamortizedcost(Lossislistedwith“-”)|||
|Netexposurehedgingincome(Lossislistedwith“-”)|||
|Changingincomeoffairvalue(Lossislistedwith“-”)|||
|Impairmentlossesonfinancialassets(Lossislistedwith“-”)|-161,522.25||
|Impairmentloss(Lossislistedwith“-”)|-234,019.78|152,059.06|
|Gainondisposalofassets(Lossislistedwith“-”)|181,433.34|11,116.50|
|II.Operatingprofits(Lossislistedwith“-”)|488,681,198.19|103,924,616.88|
|Add:Non-operatingincome|373.35|3.98|
|Less:Non-operatingexpense|||
|III.TotalProfit(Lossislistedwith“-”)|488,681,571.54|103,924,620.86|
|Less:Incometaxes|3,675,740.93|4,806,491.84|
|IV.Netprofit(Netlossislistedwith“-”)|485,005,830.61|99,118,129.02|

||||
|-|-|-|
|(i)NetProfitfromcontinuingoperations(netlosslistedwith‘-”)|485,005,830.61|99,118,129.02|
|(ii)terminationofnetprofit(netlosslistedwith‘-”)|||
|V.Netafter-taxofothercomprehensiveincome|||
|(I)Othercomprehensiveincomeitemswhichwillnotbereclassifiedsubsequentlytoprofitofloss|||
|1.Changesofthedefinedbenefitplansthatre-measured|||
|2.Othercomprehensiveincomeunderequitymethodthatcannotbetransfertogain/loss|||
|3.Changeoffairvalueofinvestmentinotherequityinstrument|||
|4.Fairvaluechangeofenterprise'screditrisk|||
|5.Other|||
|(II)Othercomprehensiveincomeitemswhichwillbereclassifiedsubsequentlytoprofitorloss|||
|1.Othercomprehensiveincomeunderequitymethodthatcantransfertogain/loss|||
|2.Changeoffairvalueofotherdebtinvestment|||
|3.gain/lossoffairvaluechangesforavailable-for-salefinancialassets|||
|4.Amountoffinancialassetsre-classifytoothercomprehensiveincome|||
|5.Gain/lossofheld-to-maturityinvestmentsthatre-classifytoavailable-for-salefinancialasset|||
|6.Creditimpairmentprovisionforotherdebtinvestment|||

||||
|-|-|-|
|7.Cashflowhedgingreserve|||
|8.Translationdifferencesarisingontranslationofforeigncurrencyfinancialstatements|||
|9.Other|||
|VI.Totalcomprehensiveincome|485,005,830.61|99,118,129.02|
|VII.Earningspershare:|||
|(i)Basicearningspershare|||
|(ii)Dilutedearningspershare|||

5.ConsolidatedProfitStatement(formtheyear-begintotheperiod-end)
InRMB
||||
|-|-|-|
|Item|CurrentPeriod|LastPeriod|
|I.Totaloperatingrevenue|38,875,940,809.07|31,766,707,068.44|
|Including:Operatingrevenue|38,875,940,809.07|31,766,707,068.44|
|Interestrevenue|||
|Insurancegained|||
|Commissionchargeandcommissionrevenue|||
|II.Totaloperatingcost|37,747,619,061.94|30,779,410,046.43|
|Including:Operatingcosts|34,669,028,279.63|28,117,497,354.04|
|Interestexpense|||
|Commissionchargeandcommissionexpense|||
|Cashsurrendervalue|||
|Netamountofexpenseofcompensation|||
|Netamountofwithdrawalofinsurancecontractreserve|||
|Bonusexpenseofguaranteeslip|||
|Reinsuranceexpense|||
|Taxandsurcharges|98,652,400.93|86,796,493.46|
|Sallingexpenses|2,246,564,429.04|1,956,325,205.63|
|Administrativeexpenses|585,528,096.51|540,513,396.10|
|R&Dexpense|||

||||
|-|-|-|
|Financecosts|147,845,855.83|78,277,597.20|
|Incl:Interestcost|256,058,467.21|129,032,902.25|
|Interestincome|103,408,606.99|49,335,302.27|
|Add:otherincomes|27,107,672.14|12,404,586.52|
|Investmentincome(Lossislistedwith“-”)|255,212,226.48|241,677,055.81|
|Incl:Investmentincomefromassociates|255,162,226.48|241,595,555.81|
|Theterminationofincomerecognitionforfinancialassetsmeasuredbyamortizedcost(Lossislistedwith“-”)|||
|Exchangeincome(Lossislistedwith“-”)|||
|Netexposurehedgingincome(Lossislistedwith“-”)|||
|Incomefromchangeoffairvalue(Lossislistedwith“-”)|||
|Impairmentlossesonfinancialassets(Lossislistedwith“-”)|-14,646,019.78|479,210.87|
|Impairmentlosses(Lossislistedwith“-”)|-831,434.15|-116,540.68|
|Gainondisposalofassets(Lossislistedwith“-”)|584,184.27|4,357,644.11|
|III.Operatingprofit(Lossislistedwith“-”)|1,395,748,376.09|1,246,098,978.64|
|Add:Non-operatingincome|6,869,502.41|7,052,562.23|
|Less:Non-operatingexpense|2,357,054.62|2,171,320.17|
|IV.Totalprofit(Lossislistedwith“-”)|1,400,260,823.88|1,250,980,220.70|
|Less:Incometaxes|272,875,954.40|240,524,754.11|
|V.Netprofit(Netlossislistedwith“-”)|1,127,384,869.48|1,010,455,466.59|
|(i)Classifybybusinesscontinuity|||
|1.NetProfitfromcontinuingoperations(netlosslistedwith‘-”)|1,127,384,869.48|1,010,455,466.59|
|2.terminationofnetprofit(netlosslistedwith‘-”)|||
|(ii)Classifybyownership|||
|1.Ownersoftheparent|962,144,066.92|926,971,570.47|
|2.Non-controllinginterests|165,240,802.56|83,483,896.12|

||
|-|
|VI.Netafter-taxofothercomprehensiveincome|
|Netafter-taxofothercomprehensiveincomeattributabletoownersofparentcompany|
|(I)Othercomprehensiveincomeitemswhichwillnotbereclassifiedsubsequentlytoprofitofloss|
|1.Changesofthedefinedbenefitplansthatre-measured|
|2.Othercomprehensiveincomeunderequitymethodthatcannotbetransfertogain/loss|
|3.Changeoffairvalueofinvestmentinotherequityinstrument|
|4.Fairvaluechangeofenterprise'screditrisk|
|5.Other|
|(ii)Othercomprehensiveincomeitemswhichwillbereclassifiedsubsequentlytoprofitorloss|
|1.Othercomprehensiveincomeunderequitymethodthatcantransfertogain/loss|
|2.Changeoffairvalueofotherdebtinvestment|
|3.gain/lossoffairvaluechangesforavailable-for-salefinancialassets|
|4.Amountoffinancialassetsre-classifytoothercomprehensiveincome|
|5.Gain/lossofheld-to-maturityinvestmentsthatre-classifytoavailable-for-salefinancialasset|
|6.Creditimpairmentprovisionforotherdebtinvestment|
|7.Cashflowhedgingreserve|

||||
|-|-|-|
|8.Translationdifferencesarisingontranslationofforeigncurrencyfinancialstatements|||
|9.Other|||
|Netafter-taxofothercomprehensiveincomeattributabletominorityshareholders|||
|VII.Totalcomprehensiveincome|1,127,384,869.48|1,010,455,466.59|
|Totalcomprehensiveincomefortheyearattributabletoshareholdersoftheparent|962,144,066.92|926,971,570.47|
|Totalcomprehensiveincomefortheyearattributabletonon-controllinginterests|165,240,802.56|83,483,896.12|
|VIII.Earningspershare:|||
|(i)Basicearningspershare|2.247|2.165|
|(ii)Dilutedearningspershare|2.247|2.165|

 As for the business merger under the same control in the Period, 0Yuan net profit realized before merger by the combinedparty,thenetprofitforcombinedpartyinlastperiodwas0Yuan.
6.ProfitStatementofParentCompany(formtheyear-begintotheperiod-end)
InRMB
||||
|-|-|-|
|Item|CurrentPeriod|LastPeriod|
|I.Operatingrevenue|3,120,629,410.26|2,587,480,358.28|
|Less:Operatingcosts|2,985,973,415.79|2,471,014,077.79|
|Taxesandsurcharge|4,483,432.58|3,462,103.37|
|Sellingexpenses|49,036,664.17|42,847,937.24|
|Administrativeexpenses|62,356,107.14|50,464,856.30|
|R&Dexpenses|||
|Financecosts|-39,885,446.76|-29,640,152.73|
|Incl:Interestexpense|38,713,629.13|31,721,163.76|
|Incl:Interestincome|80,175,392.47|62,271,142.76|
|Add:otherincome|552,592.19|1,421,335.96|
|Investmentincome(Lossislistedwith“-”)|1,081,800,975.38|619,832,149.52|
|Incl:Investmentincomefromassociates|272,540,375.14|258,317,695.20|

||||
|-|-|-|
|Theterminationofincomerecognitionforfinancialassetsmeasuredbyamortizedcost(Lossislistedwith“-”)|||
|Netexposurehedgingincome(Lossislistedwith“-”)|||
|Changingincomeoffairvalue(Lossislistedwith“-”)|||
|Impairmentlossesonfinancialassets(Lossislistedwith“-”)|-2,527,287.33|7,411.02|
|Impairmentloss(Lossislistedwith“-”)|-336,132.62|-478,894.27|
|Gainondisposalofassets(Lossislistedwith“-”)|155,358.82|11,116.50|
|II.Operatingprofit(Lossislistedwith“-”)|1,138,310,743.78|670,124,655.04|
|Add:Non-operatingincome|46,442.75|37.06|
|Less:Non-operatingexpenses||127,688.63|
|III.TotalProfit(Lossislistedwith“-”)|1,138,357,186.53|669,997,003.47|
|Less:Incometaxes|12,674,965.45|11,099,365.68|
|IV.Netprofit(Netlossislistedwith“-”)|1,125,682,221.08|658,897,637.79|
|(i)NetProfitfromcontinuingoperations(netlosslistedwith‘-”)|1,125,682,221.08|658,897,637.79|
|(ii)terminationofnetprofit(netlosslistedwith‘-”)|||
|V.Netafter-taxofothercomprehensiveincome|||
|(I)Othercomprehensiveincomeitemswhichwillnotbereclassifiedsubsequentlytoprofitofloss|||
|1.Changesofthedefinedbenefitplansthatre-measured|||
|2.Othercomprehensiveincomeunderequitymethodthatcannotbetransfertogain/loss|||
|3.Changeoffairvalueofinvestmentinotherequityinstrument|||
|4.Fairvaluechangeof|||

||||
|-|-|-|
|enterprise'screditrisk|||
|5.Other|||
|(II)Othercomprehensiveincomeitemswhichwillbereclassifiedsubsequentlytoprofitorloss|||
|1.Othercomprehensiveincomeunderequitymethodthatcantransfertogain/loss|||
|2.Changeoffairvalueofotherdebtinvestment|||
|3.gain/lossoffairvaluechangesforavailable-for-salefinancialassets|||
|4.Amountoffinancialassetsre-classifytoothercomprehensiveincome|||
|5.Gain/lossofheld-to-maturityinvestmentsthatre-classifytoavailable-for-salefinancialasset|||
|6.Creditimpairmentprovisionforotherdebtinvestment|||
|7.Cashflowhedgingreserve|||
|8.Translationdifferencesarisingontranslationofforeigncurrencyfinancialstatements|||
|9.Other|||
|VI.Totalcomprehensiveincome|1,125,682,221.08|658,897,637.79|
|VII.Earningspershare:|||
|(i)Basicearningspershare|||
|(ii)Dilutedearningspershare|||

7.ConsolidatedCashFlowStatement(formtheyear-begintotheperiod-end)
InRMB
||||
|-|-|-|
|Item|CurrentPeriod|LastPeriod|
|I.Cashflowsarisingfromoperatingactivities:|||

||||
|-|-|-|
|Cashreceivedfromsalesofgoodorrenderingofservices|39,464,106,244.18|33,576,126,717.79|
|Netincreaseofcustomerdepositandinterbankdeposit|||
|Netincreaseofloanfromcentralbank|||
|Netincreaseofcapitalborrowedfromotherfinancialinstitution|||
|Cashreceivedfromoriginalinsurancecontractfee|||
|Netcashreceivedfromreinsurancebusiness|||
|Netincreaseofinsuredsavingsandinvestment|||
|Cashreceivedfrominterest,commissionchargeandcommission|||
|Netincreaseofcapitalborrowed|||
|Netincreaseofreturnedbusinesscapital|||
|Netcashreceivedbyagentsinsaleandpurchaseofsecurities|||
|Taxrefunds|3,508,074.72|1,714,760.21|
|Cashreceiptsrelatedtootheroperatingactivities|497,412,494.23|503,409,429.80|
|Sub-totalofcashinflowsfromoperatingactivities|39,965,026,813.13|34,081,250,907.80|
|Cashpaidforgoodsandservices|35,594,093,946.44|30,058,268,141.08|
|Netincreaseofcustomerloansandadvances|||
|Netincreaseofdepositsincentralbankandinterbank|||
|Cashpaidfororiginalinsurancecontractcompensation|||
|Netincreaseofcapitallent|||
|Cashpaidforinterest,commissionchargeandcommission|||
|Cashpaidforbonusofguaranteeslip|||

||||
|-|-|-|
|Cashpaidtoandonbehalfofemployees|1,592,033,194.68|1,392,220,211.12|
|Cashpaidforalltypesoftaxes|941,789,797.45|818,864,295.31|
|Cashpaymentsrelatedtootheroperatingactivities|764,147,713.34|1,247,906,964.93|
|Sub-totalofcashoutflowsfromoperatingactivities|38,892,064,651.91|33,517,259,612.44|
|Netcashflowsfromoperatingactivities|1,072,962,161.22|563,991,295.36|
|II.Cashflowsarisingfrominvestingactivities:|||
|Cashreceivedfromrecoveringinvestment|||
|Cashreceivedfromreturnsoninvestments|78,242,963.78|130,963,345.37|
|Netcashreceivedfromdisposaloffixed,intangibleassetsandotherlong-termassets|4,967,658.92|5,751,674.16|
|Netcashreceivedfromdisposalofsubsidiariesandotherunits|||
|Cashreceiptsrelatedtootherinvestingactivities|4,514,498.90|101,261,607.73|
|Sub-totalofcashinflowsfrominvestingactivities|87,725,121.60|237,976,627.26|
|Cashpaidforacquisitionoffixedassets,intangibleassetsandotherlong-termassets|162,770,914.81|150,353,192.93|
|Cashpaidforacquisitionofinvestments|84,539,317.61|90,000,000.00|
|Netincreaseofmortgagedloans|||
|Netcashpaidfromdisposalofsubsidiariesandotherbusinessunits|5,328,000.00||
|Cashpaymentsrelatedtootherinvestingactivities|1,603,306.28|79,921,476.82|
|Sub-totalofcashoutflowsfrominvestingactivitiesactivities|254,241,538.70|320,274,669.75|
|Netcashflowsarisingfrominvestingactivities|-166,516,417.10|-82,298,042.49|
|III.Cashflowsarisingfromfinancing|||

||||
|-|-|-|
|activities|||
|Cashproceedsfrominvestmentsbyothers|44,548,000.00|2,788,851,200.00|
|Incl:Cashproceedsfromsubsidiaryinvestmentsbynon-controllingshareholders|44,548,000.00|2,788,851,200.00|
|Cashreceivedfromborrowings|16,700,000.00|49,670,200.30|
|Cashreceiptsrelatedtootherfinancingactivities|1,967,629.61|108,949,307.54|
|Subtotalofcashinflowfromfinancingactivities|63,215,629.61|2,947,470,707.84|
|Cashrepaymentsfordebts|73,307,142.79|79,670,200.30|
|Cashpaymentsfordistributionofdividendsorprofitandinterestexpenses|450,504,620.79|276,628,059.98|
|Incl:Profitanddividendspaidtonon-controllingshareholdersofsubsidiaries|28,493,123.11|56,858,945.30|
|Cashpaymentsrelatedtootherfinancingactivitiess|604,680,365.03|60,658,096.82|
|Subtotalofcashoutflowfromfinancingactivities|1,128,492,128.61|416,956,357.10|
|Netcashflowsfromfinancingactivities|-1,065,276,499.00|2,530,514,350.74|
|IV.EffectofforeignexchangeratechangesoncashandcashequivalentsInfluenceoncashandcashequivalentsduetofluctuationinexchangerate|-175,994.42|-314,517.97|
|V.Netincreaseincashandcashequivalents|-159,006,749.30|3,011,893,085.64|
|Add:Cashandcashequivalentsatbeginningoftheyear|7,632,117,020.77|3,673,498,691.48|
|VI.Cashandcashequivalentsatendofyear|7,473,110,271.47|6,685,391,777.12|

8.CashFlowStatementofParentCompany(formtheyear-begintotheperiod-end)
InRMB
||||
|-|-|-|
|Item|CurrentPeriod|LastPeriod|
|I.Cashflowsarisingfromoperatingactivities:|||

||||
|-|-|-|
|Cashreceivedfromsalesofgoodorrenderingofservices|3,217,890,947.38|2,681,236,630.70|
|Write-backoftaxreceived|||
|Cashreceiptsrelatedtootheroperatingactivities|32,674,054.58|91,958,196.80|
|Sub-totalofcashinflowsfromoperatingactivities|3,250,565,001.96|2,773,194,827.50|
|Cashpaidforgoodsandservices|3,191,926,190.64|2,559,377,589.52|
|Cashpaidtoandonbehalfofemployees|73,601,798.69|61,913,310.95|
|Cashpaidforalltypesoftaxes|43,156,828.71|29,801,808.96|
|Cashpaymentsrelatedtootheroperatingactivities|24,724,274.57|45,140,599.54|
|Subtotalofcashoutflowfromoperatingactivities|3,333,409,092.61|2,696,233,308.97|
|Netcashflowsarisingfromoperatingactivities|-82,844,090.65|76,961,518.53|
|II.Cashflowsarisingfrominvestingactivities:|||
|Cashreceivedfromrecoveringinvestment|||
|Cashreceivedfromreturnsofinvestments|619,976,538.54|255,904,643.39|
|Netcashreceivedfromdisposaloffixedassets,intangibleassetsandotherlong-termassets|3,961,383.00|35,200.00|
|Netcashreceivedfromdisposalofsubsidiariesandotherunits|||
|Cashreceiptsrelatedtootherinvestingactivities|1,482,390,000.00|1,218,035,586.01|
|Subtotalofcashinflowfrominvestingactivities|2,106,327,921.54|1,473,975,429.40|
|Cashpaidforacquisitionoffixedassets,intangibleassetsandotherlong-termassets|6,777,035.03|8,607,026.77|
|Cashpaidforinvestment|19,998,000.00|90,000,000.00|
|Netcashreceivedfromsubsidiariesandotherunitsobtained|||

||||
|-|-|-|
|Cashpaymentsrelatedtootherinvestingactivities|1,812,850,181.28|1,267,321,606.82|
|Subtotalofcashoutflowfrominvestingactivities|1,839,625,216.31|1,365,928,633.59|
|Netcashflowsfrominvestingactivitiesactivities|266,702,705.23|108,046,795.81|
|III.Cashflowsarisingfromfinancingactivities:|||
|Cashreceivedfromabsorbinginvestment|||
|Cashreceivedfromborrowings|10,000,000.00|10,000,000.00|
|Cashreceiptsrelatedtootherfinancingactivities|18,437,509,464.22|12,559,913,378.52|
|Subtotalofcashinflowfromfinancingactivities|18,447,509,464.22|12,569,913,378.52|
|Cashrepaymentsfordebts|10,000,000.00|10,000,000.00|
|Cashpaymentsfordistributionofdividends,profitorinterestexpenses|191,576,803.94|153,116,428.79|
|Cashpaymentsrelatedtootherfinancingactivities|17,703,057,206.85|12,723,602,657.57|
|Subtotalofcashoutflowfromfinancingactivities|17,904,634,010.79|12,886,719,086.36|
|Netcashflowsfromfinancingactivities|542,875,453.43|-316,805,707.84|
|IV..Effectofforeignexchangeratechangesoncashandcashequivalents|-175,994.42|-314,517.97|
|V.Netincreaseincashandcashequivalents|726,558,073.59|-132,111,911.47|
|Add:Cashandcashequivalentsatbeginningoftheyear|1,817,654,598.01|1,776,696,342.87|
|VI.Cashandcashequivalentsatendofyear|2,544,212,671.60|1,644,584,431.40|

II. Financialstatement adjustment
1. Relevant items of the financial statement at beginning of the year when implementing the new financial instrumentstandards,newrevenuestandardsornewleasingstandardssince2019
√Applicable□Notapplicable
ConsolidatedBalanceSheet
InRMB
|||||
|-|-|-|-|
|Item|2018-12-31|2019-01-01|Adjustment|
|Currentassets:||||
|Monetaryfunds|8,089,781,304.56|8,089,781,304.56||
|Settlementprovisions||||
|Capitallent||||
|Tradablefinancialassets||||
|Financialassetsmeasuredbyfairvalueandwithvariationreckonedintocurrentgains/losses||||
|Derivativefinancialassets||||
|Notereceivable|1,357,311,929.63|789,536,654.23|-567,775,275.40|
|Accountreceivable|9,336,861,647.92|9,336,861,647.92||
|Receivablefinancing||567,775,275.40|567,775,275.40|
|Advancestosuppliers|583,484,515.95|419,443,944.83|-164,040,571.12|
|Insurancereceivable||||
|Reinsurancereceivables||||
|Contractreserveofreinsurancereceivable||||
|Otherreceivables|643,493,359.32|643,493,359.32||
|Including:Interestreceivable|8,223,327.64|8,223,327.64||
|Dividendreceivable||||
|Buyingbackthesaleoffinancialassets||||
|Inventories|4,389,335,942.19|4,389,335,942.19||
|Contractualassets||||
|Assetsheldforsale||||
|Non-currentassetduewithinoneyear||||
|Othercurrentassets|95,347,629.18|95,347,629.18||
|Totalcurrentassets|24,495,616,328.75|24,331,575,757.63|-164,040,571.12|
|Non-currentassets:||||

|||||
|-|-|-|-|
|Loansandpaymentsonbehalf||||
|Debtinvestment||||
|Financeassetavailableforsales||||
|Otherdebtinvestment||||
|Held-to-maturityinvestment||||
|Long-termaccountreceivable||||
|Long-termequityinvestment|1,880,393,786.10|1,880,393,786.10||
|Otherequityinstrumentsinvestment|13,685,760.00|13,685,760.00||
|Othernon-currentfinancialassets|140,000,000.00|140,000,000.00||
|Investmentproperties|144,894,495.97|144,894,495.97||
|Fixedassets|607,933,827.67|594,067,973.91|-13,865,853.76|
|Constructioninprogress|36,412,614.61|36,412,614.61||
|Productivebiologicalasset||||
|Oilandgasasset||||
|Right-of-useassets||1,782,725,159.78|1,782,725,159.78|
|Intangibleassets|319,207,126.15|318,693,082.72|-514,043.43|
|ExpenseonResearchandDevelopment||||
|Goodwill|833,547,800.60|833,547,800.60||
|Long-termprepaidexpenses|311,328,706.46|311,328,706.46||
|Deferredtaxassets|74,914,209.95|74,914,209.95||
|Othernon-currentasset|72,365,863.71|58,168,919.11|-14,196,944.60|
|Totalnon-currentasset|4,434,684,191.22|6,188,832,509.21|1,754,148,317.99|
|Totalassets|28,930,300,519.97|30,520,408,266.84|1,590,107,746.87|
|Currentliabilities:||||
|Short-termborrowings|2,597,652,702.43|2,597,652,702.43||
|Loanfromcentralbank||||

|||||
|-|-|-|-|
|Capitalborrowed||||
|Transactionalfinancialliability||||
|Financialliabilitymeasuredbyfairvalueandwithvariationreckonedintocurrentgains/losses||||
|Derivativefinancialliability||||
|Notepayable|3,416,755,681.80|3,416,755,681.80||
|Accountpayable|6,468,535,961.17|6,468,535,961.17||
|Accountsreceivedinadvance||||
|Contractualliability|255,590,612.37|255,590,612.37||
|Sellingfinancialassetofrepurchase||||
|Absorbingdepositandinterbankdeposit||||
|Security trading ofagency||||
|Securitysalesofagency||||
|Employeebenefitspayable|231,866,407.40|231,866,407.40||
|Taxespayable|241,980,412.72|241,980,412.72||
|Otheraccountpayable|1,539,436,971.93|1,539,436,971.93||
|Incl:Interestpayable|21,906,660.63|21,906,660.63||
|Dividendpayable|6,389,320.96|6,389,320.96||
|Commissionchargeandcommissionpayable||||
|Reinsurancepayable||||
|Liabilityheldforsale||||
|Non-currentliabilitiesduewithinoneyear|5,861,324.37|495,132,751.96|489,271,427.59|
|Othercurrentliabilities|292,465.75|292,465.75||
|Totalcurrentliabilities|14,757,972,539.94|15,247,243,967.53|489,271,427.59|
|Non-currentliabilities:||||
|Insurancecontractreserve||||

|||||
|-|-|-|-|
|Long-termborrowings|31,600,000.00|31,600,000.00||
|Bondspayable||||
|Including:Preferredstock||||
|Perpetualcapitalsecurities||||
|Leaseliability||1,104,600,297.80|1,104,600,297.80|
|Long-termpayable|4,563,978.52|800,000.00|-3,763,978.52|
|Long-termemployeebenefitspayable|2,050,000.00|2,050,000.00||
|Accrualliability||||
|Deferredincome|91,491,170.40|91,491,170.40||
|Deferredtaxliabilities|67,605,161.88|67,605,161.88||
|Othernon-currentliabilities|69,241,176.18|69,241,176.18||
|Totalnon-currentliabilities|266,551,486.98|1,367,387,806.26|1,100,836,319.28|
|Totalliabilities|15,024,524,026.92|16,614,631,773.79|1,590,107,746.87|
|Owner’sequity:||||
|Sharecapital|428,126,983.00|428,126,983.00||
|Otherequityinstrument||||
|Including:Preferredstock||||
|Perpetualcapitalsecurities||||
|Capitalsurplus|4,320,984,981.51|4,320,984,981.51||
|Less:Inventoryshares||||
|Othercomprehensiveincome||||
|Reasonablereserve||||
|Surplusreserve|214,063,491.50|214,063,491.50||
|Provisionofgeneralrisk||||
|Retainedearnings|6,655,257,147.27|6,655,257,147.27||
|Shareholders’equityattributabletoshareholdersoftheparent|11,618,432,603.28|11,618,432,603.28||
|Non-controlling|2,287,343,889.77|2,287,343,889.77||

|||||
|-|-|-|-|
|interests||||
|Totalshareholders’equity|13,905,776,493.05|13,905,776,493.05||
|Totalliabilitiesandshareholders’equity|28,930,300,519.97|30,520,408,266.84|1,590,107,746.87|

Statementofadjustment
BalanceSheetofParentCompany
InRMB
|||||
|-|-|-|-|
|Item|2018-12-31|2019-01-01|Adjustment|
|Currentassets:||||
|Cashandbankbalances|1,817,654,598.01|1,817,654,598.01||
|Tradablefinancialassets||||
|Financialassetsmeasuredbyfairvalueandwithvariationreckonedintocurrentgains/losses||||
|Derivativefinancialassets||||
|Notereceivable|63,870,980.39|34,154,774.75|-29,716,205.64|
|Accountreceivable|631,236,593.94|631,236,593.94||
|Receivablefinancing||29,716,205.64|29,716,205.64|
|Advancestosuppliers|4,760,182.00|4,757,318.66|-2,863.34|
|Otherreceivable|1,541,980,883.50|1,541,980,883.50||
|Including:Interestreceivable|7,550,877.07|7,550,877.07||
|Dividendreceivable||||
|Inventories|158,166,185.65|158,166,185.65||
|Contractualassets||||
|Assetsheldforsale||||
|Non-currentassetsmaturingwithinoneyear||||
|Othercurrentassets|39,482.38|39,482.38||
|Totalcurrentassets|4,217,708,905.87|4,217,706,042.53|-2,863.34|
|Non-currentassets:||||
|Debtinvestment||||
|Available-for-salefinancialassets||||

|||||
|-|-|-|-|
|Otherdebtinvestment||||
|Held-to-maturityinvestments||||
|Long-termreceivables||||
|Long-termequityinvestments|7,432,906,692.24|7,432,906,692.24||
|Investmentinotherequityinstrument||||
|Othernon-currentfinancialassets|140,000,000.00|140,000,000.00||
|Investmentproperties|1,955,854.46|1,955,854.46||
|Fixedassets|21,362,422.03|21,362,422.03||
|Constructioninprogress||||
|Productivebiologicalassets||||
|Oilandnaturalgasassets||||
|Right-of-useassets||6,827,171.38|6,827,171.38|
|Intangibleassets|2,452,222.51|2,452,222.51||
|Researchanddevelopmentcosts||||
|Goodwill||||
|Long-termdeferredexpenses|7,481,809.53|7,481,809.53||
|Deferredincometaxassets||||
|Othernon-currentassets|7,000,000.00|7,000,000.00||
|Totalnon-currentassets|7,613,159,000.77|7,619,986,172.15|6,827,171.38|
|Totalassets|11,830,867,906.64|11,837,692,214.68|6,824,308.04|
|Currentliabilities:||||
|Short-termborrowings|539,000,000.00|539,000,000.00||
|Transactionalfinancialliability||||
|Financialliabilitymeasuredbyfairvalueandwithvariationreckonedintocurrentgains/losses||||

|||||
|-|-|-|-|
|Derivativefinancialliability||||
|Notespayable|252,317,800.78|252,317,800.78||
|Accountpayable|442,049,241.22|442,049,241.22||
|Accountsreceivedinadvance||||
|Contractualliability|4,182,083.40|4,182,083.40||
|Employeebenefitspayable|36,233,563.12|36,233,563.12||
|Taxespayable|13,426,601.90|13,426,601.90||
|Otherpayable|1,481,817,856.56|1,481,817,856.56||
|Incl:Interestpayable|1,354,592.35|1,354,592.35||
|Dividendspayable||||
|Liabilityheldforsale||||
|Non-currentliabilitiesduewithinoneyear||786,068.44|786,068.44|
|Othercurrentliabilities|226,427.99|226,427.99||
|Totalcurrentliabilities|2,769,253,574.97|2,770,039,643.41|786,068.44|
|Non-currentliabilities:||||
|Long-termborrowings|31,600,000.00|31,600,000.00||
|Bondspayable||||
|Including:preferredstock||||
|Perpetualcapitalsecurities||||
|Leaseliabilities||6,038,239.60|6,038,239.60|
|Long-termpayables|800,000.00|800,000.00||
|Long-termemployeebenefitspayable|118,000.00|118,000.00||
|Accruedliabilities||||
|Deferredincome|1,687,899.50|1,687,899.50||
|Deferredtaxliabilities|2,298,426.39|2,298,426.39||
|Othernon-currentliabilities||||
|Totalnon-currentliabilities|36,504,325.89|42,542,565.49|6,038,239.60|

|||||
|-|-|-|-|
|Totalliabilities|2,805,757,900.86|2,812,582,208.90|6,824,308.04|
|Owners’equity:||||
|Sharecapital|428,126,983.00|428,126,983.00||
|Otherequityinstrument||||
|Including:preferredstock||||
|Perpetualcapitalsecurities||||
|Capitalsurplus|4,426,362,777.26|4,426,362,777.26||
|Less:Inventoryshares||||
|Othercomprehensiveincome||||
|Specialreserve||||
|Surplusreserve|214,063,491.50|214,063,491.50||
|Retainedearnings|3,956,556,754.02|3,956,556,754.02||
|Totalshareholders’equity|9,025,110,005.78|9,025,110,005.78||
|Totalliabilitiesandshareholders’equity|11,830,867,906.64|11,837,692,214.68|6,824,308.04|

Statementofadjustment
2.Explanationoncomparativedatainthe earlystageofretroactiveadjustment while implementedthe new financialinstrumentstandardsornewleasingstandardssince2019
□Applicable√Notapplicable
III. Auditreport
Whetherthe3rdquarterlyreporthasbeenauditedornot
□Yes√No
The3rdquarterlyreportoftheCompanyhasnotbeenaudited.
ChinaNationalAccordMedicinesCorporationLtd. Legal representative: Lin Zhaoxiong 24 October 2019